DOSSIER · 13F-HR · Q2 2026

TRV GP VI, LLC

$232M in tracked AUM across 4 positions as of Q2 2026.

TG
CIK 0001990716 · last filed Jun 30, 2026
Total AUM
$232M
as of Q2 2026
Holdings
4
positions
Whale Score
71
71
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026
SEC 13F Filing Analysis: TRV GP VI, LLC
1. Portfolio Overview

The filing for TRV GP VI, LLC reveals a highly specialized, concentrated investment portfolio with a high-risk, high-reward profile typical of venture capital or specialized biotechnology investment vehicles. As of the report date September 30, 2025, the total portfolio value stands at approximately $109.64 million, representing a significant growth of 70.7% from the previous quarter's $64.22 million.

The portfolio is ...

2. Key Holdings

The portfolio is dominated by early-stage to mid-stage biotechnology companies, with the top two positions commanding nearly 99% of the total assets.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
SEPN
SEPTERNA, INC.
$141M4.2M60.7%
02
SPTX
SEAPORT THEREAPEUTICS, INC.
$45M2.1M19.3%
03
RAPP
RAPPORT THERAPEUTICS, INC.
$40M969K17.4%
04
TNGX
TANGO THERAPEUTICS, INC.
$6M194K2.6%

Filing history

2026Q2Jun 30
$232M 71.3%
4 positionsView →
2026Q1Mar 31
$136M 8.7%
3 positionsView →
2025Q4Dec 31
$149M 35.5%
3 positionsView →
2025Q3Sep 30
$110M 70.7%
3 positionsView →
2025Q2Jun 30
$64M 53.0%
4 positionsLocked
2025Q1Mar 31
$42M 64.1%
4 positionsLocked
2024Q4Dec 31
$117M
4 positionsLocked